SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2018 / Cilt: 48 - Sayı: 6

Efficacy of 180° Cyclodiode Transscleral Photocoagulation for Refractory Glaucoma

Dirençli Glokomda 180° Transskleral Siklodiod Fotokoagülasyon Tedavisinin Etkinliği

Sibel KOCABEYOĞLU
Murat İRKEÇ
Mehmet Cem MOCAN
Figen BEZCİ AYGÜN
Pages
299–303
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mean postoperative IOP level (23.9±8.5 mmHg) was significantly lower than preoperative IOP (39.2±8.9 mmHg) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate the efficacy and safety of transscleral cyclophotocoagulation (TS-CPC) limited to 180° of ciliary body ablation in patients with various forms of refractory glaucoma.
📊
Key Findings & Data:Materials and Methods: Thirty eyes with refractory glaucoma treated with 180° TS-CPC were retrospectively analyzed for intraocular pressure (IOP) reduction and success rates.
💡
Conclusion & Impact:The mean postoperative IOP level (23.9±8.5 mmHg) was significantly lower than preoperative IOP (39.2±8.9 mmHg) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate the efficacy and safety of transscleral cyclophotocoagulation (TS-CPC) limited to 180° of ciliary body ablation in patients with various forms of refractory glaucoma. Materials and Methods: Thirty eyes with refractory glaucoma treated with 180° TS-CPC were retrospectively analyzed for intraocular pressure (IOP) reduction and success rates. Patients’ age, gender, type of glaucoma, number of diode laser treatment sessions, postoperative complications, number of hypotensive medications required to control IOP, and best corrected visual acuity (BCVA) were evaluated. The criteria for success were defined as postoperative IOP 20% decrease in IOP with or without additional medical treatment. Results: The mean age of all patients was 51.3±26.9 years (range, 1-84 years). The mean postoperative IOP level (23.9±8.5 mmHg) was significantly lower than preoperative IOP (39.2±8.9 mmHg) (p

Özet

Amaç: Dirençli glokomlu hastalarda 180° siliyer cisim ablasyonu ile sınırlandırılmış transskleral diod lazer siklofotokoagülasyon(TSDLS) tedavisinin etkinliğini ve güvenilirliğini değerlendirmektir.Gereç ve Yöntem: Dirençli glokomu olan ve 180° TSDLS ile tedavi edilen 30 göz, göz içi basıncı (GİB) düşme ve başarı oranlarıaçısından retrospektif olarak analiz edildi. Hastaların yaşı, cinsiyeti, glokom tipi, TSDLS sayısı, postoperatif komplikasyonları, antiglokomatözilaç sayısı ve en iyi düzeltilmiş görme keskinliği (EİDGK) değerlendirildi. Başarı kriterleri lazer işlemi sonrası ek bir medikaltedavi ile veya tedavisiz, nihai GİB düzeyinin %20 düşüş olması olarak tanımlandı.Bulgular: Hastaların yaş ortalaması 51,3±26,9 yıl (dağılım=1-84 yıl) idi. Tedavi sonrası GİB düzeyinin (23,9±8,5 mmHg) preoperatifGİB’e göre (39,2±8,9 mmHg) anlamlı olarak düştüğü belirlendi (p

🔖

Cite This Article

KOCABEYOĞLU, S., İRKEÇ, M., MOCAN, M. C., AYGÜN, F. B. (2022). Efficacy of 180° Cyclodiode Transscleral Photocoagulation for Refractory Glaucoma. Türk Oftalmoloji Dergisi, Cilt: 48 - Sayı: 6, 299–303. https://ajindex.com/articles/637767

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Mistlberger A, Liebmann JM, Tschiderer H, Ritch R, Ruckhofer J, Grabner G. Diode laser transscleral cyclophotocoagulation for refractory glaucoma. J Glaucoma. 2001;10:288-293.
  2. Murphy CC, Burnett CA, Spry PG, Broadway DC, Diamond JP. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2003; 87:1252-1257. Ishida K. Update on results and complications of cyclophotocoagulation. Curr Opin Ophthalmol. 2013;24:102-110.
  3. Mandal S, Gadia R, Ashar J. Diode Laser Cyclophotocoagulation. Journal of Current Glaucoma Practice. 2009;3:47-59.
  4. Pantcheva MB, Kahook MY, Schuman JS, Noecker RJ. Comparison of acute structural and histopathological changes in human autopsy eyes after endoscopic cyclophotocoagulation and trans-scleral cyclophotocoagulation. Br J Ophthalmol. 2007;91:248-252.
  5. Zhekov I, Janjua R, Shahid H, Sarkies N, Martin KR, White AJ. A retrospective analysis of long-term outcomes following a single episode of transscleral cyclodiode laser treatment in patients with glaucoma. BMJ Open. 2013:3. Egbert PR, Fiadoyor S, Budenz DL, Dadzie P, Byrd S. Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open-angle glaucoma. Arch Ophthalmol. 2001;119:345-350.
  6. Gupta V, Agarwal HC. Contact trans-scleral diode laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population. Indian J Ophthalmol. 2000; 48:295-300.
  7. Schlote T, Derse M, Rassmann K, Nicaeus T, Dietz K, Thiel HJ. Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. J Glaucoma. 2001;10:294-301.
  8. Kosoko O, Gaasterland DE, Pollack IP, Enger CL. Long-term outcome of initial ciliary ablation with contact diode laser transscleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group. Ophthalmology. 1996;103:1294-1302.
  9. Singh K, Jain D, Veerwal V. Diode laser cyclophotocoagulation in Indian eyes: efficacy and safety. Int Ophthalmol. 2017;37:79-84.
  10. Threlkeld AB, Johnson MH. Contact transscleral diode cyclophotocoagulation for refractory glaucoma. J Glaucoma. 1999;8:3-7.
  11. Oguri A, Takahashi E, Tomita G, Yamamoto T, Jikihara S, Kitazawa Y. Transscleral cyclophotocoagulation with the diode laser for neovascular glaucoma. Ophthalmic Surg Lasers. 1998;29:722-727.
  12. Spencer AF, Vernon SA. “Cyclodiode”: results of a standard protocol. Br J Ophthalmol. 1999;83:311-316.
  13. Bitirgen G, Okka M, Bozkurt B, Doğru İ